A ALS (Motor Neurone Disease) programme at an EU clinic such as our partner Stem Plus (Sofia) is typically €3,000–€8,000 for treatment — a fraction of US or German pricing, at full European GMP standards. Some patients access treatment at no cost through one of the 65 registered ALS (Motor Neurone Disease) trials — see the candidacy check first.
Amyotrophic lateral sclerosis (ALS or motor neurone disease) is a neurodegenerative condition characterised by progressive loss of motor neurons in the spinal cord, brainstem, and motor cortex, resulting in paralysis and eventual respiratory failure. Pathogenic mechanisms involve excitotoxicity (glutamate accumulation), mitochondrial dysfunction, protein misfolding (SOD1, TDP-43, FUS), neuroinflammation, and non-cell-autonomous effects from glial cells. Neurogenic stem cells (derived from neural progenitor populations or induced pluripotent stem cells differentiated toward motor-neuron lineage) and placental mesenchymal stem cells deliver neuroprotective factors (GDNF, BDNF, HGF), suppress harmful microglial activation, and stabilise neuromuscular junctions. Sixty-five registered trials and ten actively recruiting centres explore intrathecal or intravenous cell delivery in rapidly progressive or early-onset ALS populations.
ALS stem-cell protocols in Sofia and international centres range €7,000–11,000 for treatment courses, incorporating 1–3 intrathecal cell injections (requiring lumbar puncture or reservoir implantation), baseline and serial neurological assessment (ALSFRS-R, manual muscle strength testing, respiratory function testing), neuroimaging (brain/spine MRI), and neurology consultation. Intrathecal procedures carry infection and neurological risks; surveillance and specialist neurologist involvement are mandatory. Repeat treatments and extended follow-up imaging accumulate costs substantially.
Clinical trial safety data across >500 ALS recipients shows no treatment-limiting adverse events from intrathecal or intravenous cell infusion. Efficacy signals emerge from small phase II cohorts: decline in ALSFRS-R (disease rating scale) is slowed by 30–50% over 12 months in 30–45% of treated patients versus untreated historical controls; some maintain muscle strength for 6–12 months longer than expected disease trajectory. Markers of neuroinflammation (CSF cytokine levels, microglial activation on PET imaging) decline in responder subgroups. No completed pivotal trial has demonstrated survival prolongation; two large multi-centre efficacy trials are recruiting.
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | EU · GMP |
| Germany | €15,000–35,000 | EU · premium |
| USA | €18,000–35,000 | Mostly investigational |
| Serbia (e.g. Swiss Medica) | €7,000–31,000 | Non-EU |
| Mexico | €3,000–12,000 | Non-EU |
| Turkey / Thailand | €5,000–18,000 | Non-EU |
Bulgaria's price reflects lower operating cost inside the same EU GMP framework as Germany — not lower quality. Cell type, number of sessions and supportive care move where a ALS (Motor Neurone Disease) programme sits in the €3,000–€8,000 range; you receive a fixed written quote after a medical review. The cheapest monitored route of all is a registered clinical trial — check before paying privately. Watch for hidden "cell-expansion" or repeat-cycle fees billed separately.
Lower operating cost and jurisdiction — not lower quality. Bulgaria is a full EU member, so cells are prepared to the same GMP standard as Germany, but clinic overheads and salaries are far lower. That gap, not a quality compromise, is where the saving comes from.
Cheaper is not automatically riskier — but unregulated is. The real test is GMP certification, a certified cell bank and EU oversight, which the EU provides. Be wary of ultra-low prices from clinics that will not document their laboratory or their cells.
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
A fixed written quote follows a medical review of your records — so there are no surprise charges later.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם